Business, energy, technology, markets and global industry news from Business News Today

AACR 2026

PharmaDeviceNews AACR 2026
Pharma & Biotech

Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?

Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.

Read More
Pharma & Biotech

Ensem Therapeutics puts pan-KRAS and WRN into focus as AACR 2026 sharpens its precision oncology pitch

Read how Ensem Therapeutics is positioning ETX-929 and ETX-880 in the KRAS and MSI-H oncology races at AACR 2026.

Read More
Pharma & Biotech

Can Volastra Therapeutics turn KIF18A inhibition into a pan-cancer precision oncology platform?

Volastra Therapeutics unveils AACR 2026 biomarker and combination data for KIF18A inhibitors. Read what this means for oncology development.

Read More
Pharma & Biotech

Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors

Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.

Read More
Pharma & Biotech

Can OncoNano Medicine’s ON-BOARD platform solve antigen limits in solid tumor drug delivery?

OncoNano Medicine’s AACR 2026 data spotlight ON-BOARD and ONM-421. Read why pH-targeted tumor delivery could reshape oncology development.

Read More
Representative image of acute myeloid leukemia research, illustrating how Orum Therapeutics’ ORM-1153 AACR 2026 data are drawing attention to CD123-targeting degrader-antibody conjugates in AML.
Pharma & Biotech

Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention

Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.

Read More
Representative image of a scientist in a cancer research laboratory, illustrating Onchilles Pharma’s AACR 2026 preclinical update on the NEU-002 systemic solid tumor therapy program.
Pharma & Biotech

How NEU-002 could reshape Onchilles Pharma’s systemic solid tumor strategy after AACR 2026

Onchilles Pharma’s NEU-002 showed systemic anti-tumor activity at AACR 2026. Read what the preclinical data could mean for solid tumor development.

Read More
Representative image of lung cancer immunotherapy research as Innate Pharma advances IPH5201 in the MATISSE Phase 2 trial for resectable non-small cell lung cancer at AACR 2026.
Pharma & Biotech

Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis

Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.

Read More
Representative image of bispecific antibody drug conjugate research as NEOK Bio highlights NEOK001 and NEOK002 at AACR 2026, drawing attention to the next wave of solid tumor ADC development.
Pharma & Biotech

Can bispecific ADCs give NEOK Bio a more credible route into solid tumor drug development?

NEOK Bio unveiled AACR 2026 data for NEOK001 and NEOK002. Read how its bispecific ADC strategy could reshape solid tumor competition.

Read More
Representative image of single-cell tumor analysis and clonal growth profiling, illustrating how SingleCell Biotechnology’s AACR 2026 assay could help link cancer cell behavior to molecular signatures in oncology drug discovery.
Pharma & Biotech

AACR 2026: SingleCell Biotechnology targets oncology’s blind spot with functional single-cell profiling

Read how SingleCell Biotechnology’s AACR 2026 assay could reshape tumor heterogeneity research and oncology drug development.

Read More